The FDA has sent its first untitled letter of 2025, hitting Edenbridge Pharmaceuticals with a notice after assessing an exhibit booth panel’s compliance with the rules on promoting prescription ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback